logo

For the Inventor, By the Inventor

Glen Mills, PA, United States of America

Hong Liu

This inventor holds 13 USPTO granted patents and 4 published patent applications. Top assignees: Bristol-Myers Squibb Pharma Company, Dupont Pharmaceuticals Company, Bristol-Myers Squibb Compnay. Active years: 2003-2010.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hong Liu. Retrieved from https://idiyas.com/inventor/hong-liu-h3157guk

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 13 

% Patents Active = 84.6

Average Co-Inventor Count = 3.4

ph-index = 13

Forward Citations = 186(Granted Patents)


Company Filing History:

goldMedal9 out of 234 
 
Bristol-Myers Squibb Pharma Company
 patents
silverMedal2 out of 106 
 
Dupont Pharmaceuticals Company
 patents
bronzeMedal1 out of 3,745 
 
Bristol-Myers Squibb Compnay
 patents
4. 1 out of 10 
 
Bristol-Myers Squibb Pharma Corporation
 patents

Years Active: 2003-2010

Loading Chart...
13 patents (USPTO):Explore Patents
1. 7655647 - Substituted lactams as inhibitors of Aβ protein production (2010-02-02),
2. 7498324 - Substituted lactams as inhibitors of Aβ protein production (2009-03-03),
3. 7423033 - Hydroxyalkanoylaminolactams and related structures as inhibitors of aβ protein production (2008-09-09),
4. 7390802 - Substituted lactams as inhibitors of Aβ protein production (2008-06-24),
5. 7342008 - Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production (2008-03-11),
6. 7276495 - Substituted lactams as inhibitors of Aβ protein production (2007-10-02),
7. 7112583 - Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production (2006-09-26),
8. 6960576 - Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production (2005-11-01),
9. 6900199 - Substituted lactams as inhibitors of Aβ protein production (2005-05-31),
10. 6713476 - Substituted cycloalkyls as inhibitors of a beta protein production (2004-03-30),
11. 6632812 - Substituted lactams as inhibitors of A&bgr; protein production (2003-10-14),
12. 6525044 - Succinoylamino carbocycles and heterocycles as inhibitors of a-&bgr; protein production (2003-02-25),
13. 6503902 - Hydroxyalkanoylaminolactams and related structures as inhibitors of a &bgr; protein production (2003-01-07),

Title: The Innovative Contributions of Hong Liu

Introduction

Hong Liu is a prominent inventor based in Glen Mills, PA (US), known for her significant contributions to the field of pharmaceuticals. With a total of 13 patents to her name, she has made remarkable strides in developing novel compounds aimed at treating neurological disorders.

Latest Patents

One of her latest patents focuses on "Substituted lactams as inhibitors of Aβ protein production." This invention relates to novel lactams of Formula (I), which possess drug and bio-affecting properties. These compounds inhibit the processing of amyloid precursor protein and specifically target the production of Aβ-peptide. By doing so, they act to prevent the formation of neurological deposits of amyloid protein. This invention is particularly relevant for the treatment of neurological disorders associated with β-amyloid production, such as Alzheimer's disease and Down's Syndrome.

Career Highlights

Throughout her career, Hong Liu has worked with notable companies, including Bristol-Myers Squibb Pharma Company and DuPont Pharmaceuticals Company. Her work in these organizations has allowed her to develop and refine her innovative ideas, contributing to advancements in medical science.

Collaborations

Hong Liu has collaborated with esteemed colleagues, including Richard Eric Olson and Michael G Yang. These partnerships have further enhanced her research and development efforts in the pharmaceutical industry.

Conclusion

Hong Liu's innovative work and dedication to developing treatments for neurological disorders highlight her importance in the field of pharmaceuticals. Her contributions continue to pave the way for advancements that can significantly impact patient care and treatment options.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…